Please login to the form below

Not currently logged in
Email:
Password:

Rainer Boehm and Hervé Hoppenot join Cellectics board

French biopharma firm adds senior industry advisors

French biopharmaceutical company Cellectis has appointed Rainer Boehm and Hervé Hoppenot to its board of directors to provide strategic advice on drug commercialisation.

Boehm spent 29 years serving Novartis working in various senior management, marketing, sales, and medical affairs roles, and his expertise spans from leadership and development to business model solutions.

He said: “I am honoured to join the board and look forward to providing strategic advice to strengthen Cellectis’ market leading position. I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives.

“What Cellectis is accomplishing is transformative and we have the potential to move the needle forward for healthcare in a positive way.”

Hervé Hoppenot also joins the board of directors. He has served at Delaware, US-based Incyte Corporation for the past three years as its president and chief executive officer, and was appointed chairman of its board of directors in 2015.

He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients.

“Through its work in developing CAR-T immunotherapies, Cellectis has an opportunity to make a significant contribution to the treatment of cancer.

“I am excited to be joining the Cellectis board during this important time of growth.”

Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with Aventis – formerly Rhone Poulenc and now part of Sanofi – including vice president of oncology and head of the US oncology business unit.

André Choulika, chief executive officer of Cellectis, said: “We are delighted to welcome Rainer Boehm and Hervé Hoppenot to our board.

“Rainer’s experience in drug commercialisation will be invaluable as we work to develop the next generation CAR T-cell immunotherapies.

“Hervé brings deep expertise in oncology which will be a major benefit to our team as we continue to innovate to bring UCART product candidates to the clinic.

“With these two esteemed leaders, we are adding to the expertise of our board of directors to help guide Cellectis into our next phase.”

7th July 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics